Regulatory Approvals

Mounjaro: FDA Approves GLP-1 for Cardiovascular Risk Reduction

By

Regulatory Approvals — Mounjaro: FDA Approves GLP-1 for Cardiovascular Risk Reduction  Healthline

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. September 2, 2026.

By

Related Post

Regulatory Approvals

UniQure, after setbacks, seeks FDA approval of Huntington’s gene therapy

Regulatory Approvals

FDA approves Zimrixby (rituximab) and Garzulys (insulin aspart) biosimilars

Regulatory Approvals

FDA Approval of Essential Thrombocythemia Drug is “Important Milestone”

Financial News For All

Labor

Nearly 550 employees face layoffs as housekeeping contractor ends VCU Health contract

Labor

Amazon Teamsters Launch One-Day ULP Strike at Company’s Largest Facility

Labor

Arizona physicians unionize at Banner Health

Regulatory Approvals

Mounjaro: FDA Approves GLP-1 for Cardiovascular Risk Reduction